Valeant Pharmaceuticals International, Inc.-Product Pipeline Review-2016

Valeant Pharmaceuticals International, Inc.-Product Pipeline Review-2016


  • Products Id :- GMDHC08114CDB
  • |
  • Pages: 90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Valeant Pharmaceuticals International, Inc.-Product Pipeline Review-2016

Summary

Global Markets Direct's, Valeant Pharmaceuticals International, Inc.-Product Pipeline Review-2016', provides an overview of the Valeant Pharmaceuticals International, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Valeant Pharmaceuticals International, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Valeant Pharmaceuticals International, Inc.

The report provides overview of Valeant Pharmaceuticals International, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Valeant Pharmaceuticals International, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Valeant Pharmaceuticals International, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate Valeant Pharmaceuticals International, Inc.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Valeant Pharmaceuticals International, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Valeant Pharmaceuticals International, Inc.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Valeant Pharmaceuticals International, Inc. Snapshot 7

Valeant Pharmaceuticals International, Inc. Overview 7

Key Information 7

Key Facts 7

Valeant Pharmaceuticals International, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Valeant Pharmaceuticals International, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Combination Treatment Modalities 13

Pipeline Products-Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Pipeline Products-Out-Licensed Products 16

Out-Licensed Products/Combination Treatment Modalities 17

Valeant Pharmaceuticals International, Inc.-Pipeline Products Glance 18

Valeant Pharmaceuticals International, Inc.-Late Stage Pipeline Products 18

Pre-Registration Products/Combination Treatment Modalities 18

Phase III Products/Combination Treatment Modalities 19

Valeant Pharmaceuticals International, Inc.-Clinical Stage Pipeline Products 20

Phase II Products/Combination Treatment Modalities 20

Phase I Products/Combination Treatment Modalities 21

Valeant Pharmaceuticals International, Inc.-Early Stage Pipeline Products 22

Preclinical Products/Combination Treatment Modalities 22

Valeant Pharmaceuticals International, Inc.-Unknown Stage Pipeline Products 23

Unknown Products/Combination Treatment Modalities 23

Valeant Pharmaceuticals International, Inc.-Drug Profiles 24

brodalumab 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

(halobetasol propionate + tazarotene) 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

budesonide 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

IDP-122 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

loteprednol etabonate next generation 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

rifaximin DR 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

BLO-020 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

ezogabine 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

IDP-120 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

IDP-121 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

IDP-125 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

IDP-126 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

IDP-127 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

IDP-128 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

IDP-129 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

IDP-130 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

IDP-131 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

lapuleucel-T 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

ribavirin 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

SAL-021 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Product Description 51

Mechanism of Action 51

R&D Progress 51

SPT-201 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

metyrosine 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

BLO-021 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

IDP-123 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

IDP-124 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

VALBRO-03 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Valeant Pharmaceuticals International, Inc.-Pipeline Analysis 58

Valeant Pharmaceuticals International, Inc.-Pipeline Products by Target 58

Valeant Pharmaceuticals International, Inc.-Pipeline Products by Route of Administration 60

Valeant Pharmaceuticals International, Inc.-Pipeline Products by Molecule Type 61

Valeant Pharmaceuticals International, Inc.-Pipeline Products by Mechanism of Action 62

Valeant Pharmaceuticals International, Inc.-Recent Pipeline Updates 64

Valeant Pharmaceuticals International, Inc.-Dormant Projects 73

Valeant Pharmaceuticals International, Inc.-Discontinued Pipeline Products 75

Discontinued Pipeline Product Profiles 75

ATON-004 75

(bupropion hydrochloride + selective serotonin reuptake inhibitor) 75

brodalumab 75

CVTE-002 76

ezogabine 76

IDP-107 76

IDP-109 76

IDP-115 76

MC-5 76

methylnaltrexone bromide 76

pegaptanib sodium 76

rifaximin 76

RUS-350 77

taribavirin hydrochloride 77

tiazofurin 77

UK-279276 77

Valeant Pharmaceuticals International, Inc.-Company Statement 78

Valeant Pharmaceuticals International, Inc.-Locations And Subsidiaries 81

Head Office 81

Other Locations & Subsidiaries 81

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Tables

Valeant Pharmaceuticals International, Inc., Key Information 7

Valeant Pharmaceuticals International, Inc., Key Facts 7

Valeant Pharmaceuticals International, Inc.-Pipeline by Indication, 2016 9

Valeant Pharmaceuticals International, Inc.-Pipeline by Stage of Development, 2016 11

Valeant Pharmaceuticals International, Inc.-Monotherapy Products in Pipeline, 2016 12

Valeant Pharmaceuticals International, Inc.-Combination Treatment Modalities in Pipeline, 2016 13

Valeant Pharmaceuticals International, Inc.-Partnered Products in Pipeline, 2016 14

Valeant Pharmaceuticals International, Inc.-Partnered Products/ Combination Treatment Modalities, 2016 15

Valeant Pharmaceuticals International, Inc.-Out-Licensed Products in Pipeline, 2016 16

Valeant Pharmaceuticals International, Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2016 17

Valeant Pharmaceuticals International, Inc.-Pre-Registration, 2016 18

Valeant Pharmaceuticals International, Inc.-Phase III, 2016 19

Valeant Pharmaceuticals International, Inc.-Phase II, 2016 20

Valeant Pharmaceuticals International, Inc.-Phase I, 2016 21

Valeant Pharmaceuticals International, Inc.-Preclinical, 2016 22

Valeant Pharmaceuticals International, Inc.-Unknown, 2016 23

Valeant Pharmaceuticals International, Inc.-Pipeline by Target, 2016 59

Valeant Pharmaceuticals International, Inc.-Pipeline by Route of Administration, 2016 60

Valeant Pharmaceuticals International, Inc.-Pipeline by Molecule Type, 2016 61

Valeant Pharmaceuticals International, Inc.-Pipeline Products by Mechanism of Action, 2016 63

Valeant Pharmaceuticals International, Inc.-Recent Pipeline Updates, 2016 64

Valeant Pharmaceuticals International, Inc.-Dormant Developmental Projects,2016 73

Valeant Pharmaceuticals International, Inc.-Discontinued Pipeline Products, 2016 75

Valeant Pharmaceuticals International, Inc., Other Locations 81

Valeant Pharmaceuticals International, Inc., Subsidiaries 81

List of Figures

Valeant Pharmaceuticals International, Inc.-Pipeline by Top 10 Indication, 2016 9

Valeant Pharmaceuticals International, Inc.-Pipeline by Stage of Development, 2016 11

Valeant Pharmaceuticals International, Inc.-Monotherapy Products in Pipeline, 2016 12

Valeant Pharmaceuticals International, Inc.-Partnered Products in Pipeline, 2016 14

Valeant Pharmaceuticals International, Inc.-Out-Licensed Products in Pipeline, 2016 16

Valeant Pharmaceuticals International, Inc.-Pipeline by Top 10 Target, 2016 58

Valeant Pharmaceuticals International, Inc.-Pipeline by Route of Administration, 2016 60

Valeant Pharmaceuticals International, Inc.-Pipeline by Molecule Type, 2016 61

Valeant Pharmaceuticals International, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2016 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Current R&D Portfolio of Valeant Pharmaceuticals International, Inc.; Valeant Pharmaceuticals International, Inc.-Key Therapeutics; Valeant Pharmaceuticals International, Inc.-Pipeline Overview and Promising Molecules; Valeant Pharmaceuticals International, Inc.-News; Valeant Pharmaceuticals International, Inc.-Latest Updates; Valeant Pharmaceuticals International, Inc.-Pipeline; Valeant Pharmaceuticals International, Inc.-Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 107340
Site License
USD 3000 INR 214680
Corporate User License
USD 4500 INR 322020

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com